1. Home
  2. MBOT vs SPRO Comparison

MBOT vs SPRO Comparison

Compare MBOT & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Microbot Medical Inc.

MBOT

Microbot Medical Inc.

HOLD

Current Price

$1.03

Market Cap

75.2M

Sector

Health Care

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$1.17

Market Cap

73.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MBOT
SPRO
Founded
2010
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
75.2M
73.4M
IPO Year
2000
2017

Fundamental Metrics

Financial Performance
Metric
MBOT
SPRO
Price
$1.03
$1.17
Analyst Decision
Strong Buy
Buy
Analyst Count
3
2
Target Price
★ $6.33
$5.00
AVG Volume (30 Days)
619.4K
★ 826.9K
Earning Date
11-11-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
60.27
★ 111.81
EPS
★ N/A
N/A
Revenue
$116,887.00
★ $66,802,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$475.55
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 39.24
52 Week Low
$1.03
$1.08
52 Week High
$3.04
$3.08

Technical Indicators

Market Signals
Indicator
MBOT
SPRO
Relative Strength Index (RSI) 20.59 45.45
Support Level N/A $1.10
Resistance Level $2.21 $1.28
Average True Range (ATR) 0.06 0.07
MACD -0.01 0.00
Stochastic Oscillator 4.62 16.67

Price Performance

Historical Comparison
MBOT
SPRO

About MBOT Microbot Medical Inc.

Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: